Boston Sci invests $37M in Irish facility

Boston Scientific ($BSX) is investing €26 million ($37 million) in R&D at its Clonmel facility in Ireland. The investment will allow the company to expand its R&D and technical capabilities related to the design of its next-generation cardiac rhythm management devices manufactured at that facility. The investment is supported by the government through IDA Ireland.

"This local funding will benefit our Cardiology, Rhythm and Vascular Group by enhancing our ability to provide R&D, design and manufacturing support for our leading medical device technologies," Brad Sorenson, VP of operations for Boston Scientific, says in an IDA Ireland statement. "I am confident that, with the talent and expertise of our Clonmel staff, we can continue to successfully commercialize new life-saving innovations for our customers and their patients worldwide."

Boston Scientific established operations in Ireland in 1994 and is one of the country's largest employers, with campuses in Clonmel, Galway and Cork.

- see the IDA Ireland statement

Suggested Articles

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.

The FDA launched a center of excellence to oversee digital health products such as smartphone apps, wearable devices and software-based treatments.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.